Moon Equity Holdings Corp (MONI): Yeah, this one's fascinating... h...

StocksGoneWild · 2024-08-04T01:57:19.3770000Z

Yeah, this one's fascinating... https://www.ambit.inc/ So is this one... https://nviscommunications.com/

Play Episode

5min

Proactive - Interviews for investors

Empire Metals MD on high-purity titanium breakthrough

Empire Metals Ltd (AIM:EEE) managing director Shaun Bunn talked with Proactive about the company's latest metallurgical test results at the Pitfield project. The test work delivered an impressive 91.6% purity titanium dioxide compound—achieved on the first attempt. Bunn emphasised that this high-grade product is free from deleterious contaminants, making it suitable for further processing into titanium sponge metal or premium-grade titanium pigments. He explained that the team successfully extracted and refined the titanium-bearing minerals using gravity separation, flotation, and acid digestion techniques. The company is now focused on optimising its processing flow sheet and scaling up test work. Recent bulk metallurgical sample collections at Pitfield will support larger-scale testing, with the goal of producing more of this high-grade product for market analysis. Bunn also highlighted that the simplicity of Pitfield's mineral composition, free from heavy metals or radioactive elements, has contributed to the rapid progress in refining processes. With further purification testing ahead, Empire Metals is poised to advance its titanium strategy. For more insights from this interview, visit Proactive’s YouTube channel. Don't forget to like, subscribe, and turn on notifications for future updates. #EmpireMetals #Titanium #Mining #PitfieldProject #Metallurgy #TitaniumDioxide #MineralProcessing #MiningStocks #TitaniumSponge #Investing

Proactive - Interviews for investors

Helix Exploration expands with key acquisition at Rudyard

HeLIX Exploration PLC (AIM:HEX) CEO Bo Sears talked with Proactive's Stephen Gunnion about the company’s latest expansion at its Rudyard Project in Montana. Sears highlighted the acquisition of the Weil #1 well and its surrounding 640-acre section, which effectively doubles Helix's production capacity. The purchase, completed for $300,000, presents significant value compared to the estimated $1.3 million cost of drilling a new well. Sears explained that Rudyard’s helium potential has been known since Texaco’s 1960 drilling, but only recently has its full scale been realised. With ongoing development, Helix is transitioning from an exploration-focused approach to a development drilling program, significantly reducing risks in future wells. The company is also preparing to spud the Linda #1 well in April, pending regulatory approvals. Additionally, Sears confirmed that the Darwin #1 well is ready for production as soon as the necessary plant infrastructure is in place. On the Ingomar project, he noted that while initial gas samples were noncommercial, future drilling in the Flathead formation is planned after environmental restrictions lift in mid-June. Stay tuned to Proactive for more updates from Helix Exploration. If you found this video helpful, give it a like, subscribe to our channel, and turn on notifications for future updates. #Helium #HelixExploration #EnergySector #OilAndGas #Drilling #Investment #NaturalResources #EnergyStocks #Montana #Exploration #Mining #StockMarket

Proactive - Interviews for investors

Lisata Therapeutics expands drug discovery with GATC AI collaboration

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo talked with Proactive about the company’s strategic collaboration with GATC Health, a leader in artificial intelligence-driven drug discovery. Mazzo explained that GATC’s technology, which is recognized by Lloyd’s of London for clinical trial risk assessment, will be used to analyze Lisata’s lead candidate, certepetide, and identify potential new drug combinations. Mazzo highlighted that this collaboration will optimize Lisata’s ongoing cancer research, including trials in pancreatic ductal adenocarcinoma, cholangiocarcinoma, and other cancers. He noted that GATC’s AI technology can perform billions of simulations rapidly, potentially reducing the cost and risk of drug development. Discussing Lisata’s 2025 outlook, Mazzo described it as a "data-rich year," with upcoming results from the ASCEND trial and other studies. He emphasized the potential for certepetide in combination with immunotherapy and the company’s ongoing discussions with regulatory agencies and potential partners. To watch more interviews like this, visit Proactive’s YouTube channel. Don't forget to like this video, subscribe, and enable notifications for future updates. #LisataTherapeutics #Biotech #CancerResearch #AIinHealthcare #DrugDevelopment #ClinicalTrials #GATCHealth #Pharma #Oncology #Investing

Proactive - Interviews for investors

Immunic Therapeutics advances MS Drug , Phase 2 CALLIPER trial readout in April

Immunic Therapeutics Chief Scientific Officer Dr. Hella Kohlhof joined Steve Darling from Proactive to discuss the company’s progress in developing vidofludimus calcium, a novel treatment designed to combat multiple sclerosis (MS) through a unique dual mode of action. The drug offers neuroprotection, anti-inflammatory effects, and antiviral benefits, addressing key aspects of MS pathology. Dr. Kohlhof emphasized the urgent need for therapies that prevent disability progression in MS patients, helping them maintain independence for as long as possible. She explained that vidofludimus calcium achieves this by activating Nurr1 to promote neuroprotection while simultaneously inhibiting DHODH, reducing inflammation and Epstein-Barr virus (EBV) reactivation—both believed to play a role in MS development and progression. A major milestone for Immunic Inc. is approaching, with the phase 2 CALLIPER trial readout expected in April 2025. This study aims to confirm the drug’s neuroprotective effects, positioning it as a potential disease-modifying treatment for MS. Dr. Kohlhof also highlighted vidofludimus calcium’s strong safety and tolerability profile, noting that it is a once-daily oral tablet that requires no treatment monitoring, making it a convenient option for patients. Looking ahead, Immunic is also advancing phase 3 ENSURE trials for relapsing MS, expected to complete in 2026. With limited treatment options for progressive MS, Dr. Kohlhof underscored the high unmet medical need and the potential impact of vidofludimus calcium on improving patient outcomes worldwide. #proactiveinvestors #immunicinc #nasdaq #imux #MSResearch #VidofludimusCalcium #Neuroprotection #ImmunicInc #MSAwareness #CALLIPERTrial #MSBreakthrough #MSDisability #ClinicalTrials

Followers	496
Posts	14607
Boards Moderated	2
Alias Born	06/20/2006

Volume:	1,062,478
Day Range:	0.0065 - 0.0073
Bid:	0.0066
Ask:	0.0075
Last Trade Time:	3:49:52 PM EDT
Total Trades:	18

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

MONI Detailed Quote

Recent MONI News

More MONI News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent MONI News

Go Ad-Free